COVID-19 updates, including vaccine information, for our patients and visitors Learn More

Menu
Search

$17 Million to UC San Diego for Methamphetamine/AIDS Research

 

December 08, 2009  |  

Igor Grant, MD, professor of psychiatry at the University of California, San Diego School of Medicine, and colleagues have been awarded a $17 million grant from the National Institute on Drug Abuse to establish the Translational Methamphetamine AIDS Research Center (TMARC) at UC San Diego. Grant is director of the HIV Neurobehavioral Research Center (HNRC), a clinical research center designated and funded by the National Institute of Mental Health. HNRC researchers strive for greater understanding of how HIV enters the central nervous system and why it affects some people but does not cause neurological deficits in others.

"The establishment of TMARC will advance our knowledge of the multiple interactions that occur with HIV-induced neurological complications, substance abuse, and other comorbid disorders," noted NIDA Director Dr. Nora Volkow. "This in turn can inform the development of more responsive treatment strategies for both drug abuse and HIV, linked through the risky behaviors like needle sharing and unprotected sex that drug abuse can provoke."

The funding - $3.6 million annually for five years - will allow TMARC to research the combined effects of methamphetamine (meth) and HIV on the central nervous system. This will be the first center in the United States to study the convergent effects of meth and HIV on the brain. Its ultimate goal is to become a national resource for translational multidisciplinary research and training in the neuropathogenesis of HIV and substance abuse.

Over one million people in the USA used meth in the past year, and in communities such as San Diego over one third of people newly infected with HIV had recent meth use.

"Currently, the combined effects of meth and HIV are poorly understood," Grant said. "Although antiviral treatments for HIV have reduced mortality rates, neurological complications remain prevalent, with approximately 40% of persons treated with antivirals still experiencing neurocognitive problems such as memory and attention impairment that can reduce efficiency in everyday life. There is a converging HIV epidemic among young, gay habitual meth users, which suggests meth may be amplifying the effects of HIV."

Meth causes users to be less inhibited, decreases the sensation of pain and increases energy. In chronic meth users, it may also create an inflammatory response in the brain that makes them more susceptible to HIV, according to UC San Diego researchers. Also meth may accelerate the transformation of the virus to a more invasive form.

"A person receiving antiviral treatment is more likely to have detectable HIV if he is also a meth user," said Grant. He added that meth may increase viral replication and alter response to antiviral drugs. Because both meth and HIV affect brain function, their combined impact on neurological processes may lessen the impact of anti-retroviral treatments.

# # #

Media Contact: Debra Kain, 619-543-6163, ddkain@ucsd.edu




Media Contact

Share This Article


Related News

12/6/2022
UC San Diego Health is recognized as a 2022-2023 High Performing Hospital for Obstetric and Infant Care, the highest award a hospital can earn by U.S. News & World Report.
11/29/2022
The Urology for Social Responsibility seminar will be offered in the T. Denny Sanford Center Medical Education and Telemedicine on the UC San Diego campus from January 14 to 15, 2023.
11/22/2022
Engineers and physicians at UC San Diego have developed a device to non-invasively measure cervical nerve activity in humans, a new tool they say could potentially inform and improve treatments for pa ...
11/21/2022
UC San Diego Alpha Stem Cell Clinic awarded $8M to expand clinical trials of novel stem cell therapies. The CIRM award will advance partnerships between academic and industry experts in San Diego to e ...



Follow Us